Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma

Abstract Background The aim of this study was to identify subgroups with good or bad prognosis in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) based on immunostaining patterns with neuroendocrine markers and compare them with small cell lung carcinoma (SCLC). Methods From Janu...

Full description

Bibliographic Details
Main Authors: Kazuhiro Minami, Yugo Tanaka, Hiroyuki Ogawa, Naoe Jimbo, Wataru Nishio, Masahiro Yoshimura, Tomoo Itoh, Yoshimasa Maniwa
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:Thoracic Cancer
Subjects:
Online Access:https://doi.org/10.1111/1759-7714.13202
id doaj-45442e08f5e94d8ca92e19f1f768aed8
record_format Article
spelling doaj-45442e08f5e94d8ca92e19f1f768aed82020-11-25T02:20:09ZengWileyThoracic Cancer1759-77061759-77142019-11-0110112152216010.1111/1759-7714.13202Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinomaKazuhiro Minami0Yugo Tanaka1Hiroyuki Ogawa2Naoe Jimbo3Wataru Nishio4Masahiro Yoshimura5Tomoo Itoh6Yoshimasa Maniwa7Division of Thoracic Surgery Kobe University Graduate School of Medicine Kobe City JapanDivision of Thoracic Surgery Kobe University Graduate School of Medicine Kobe City JapanDepartment of Thoracic Surgery Hyogo Cancer Center Akashi City JapanDepartment of Diagnostic Pathology Kobe University Graduate School of Medicine Kobe City JapanDepartment of Thoracic Surgery Hyogo Cancer Center Akashi City JapanDepartment of Thoracic Surgery Hyogo Cancer Center Akashi City JapanDepartment of Diagnostic Pathology Kobe University Graduate School of Medicine Kobe City JapanDivision of Thoracic Surgery Kobe University Graduate School of Medicine Kobe City JapanAbstract Background The aim of this study was to identify subgroups with good or bad prognosis in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) based on immunostaining patterns with neuroendocrine markers and compare them with small cell lung carcinoma (SCLC). Methods From January 2001 to December 2017, of all patients with resected LCNEC and SCLC, we selected patients whose pathological tumor sizes were ≤30 mm in diameter (defined as small‐sized tumors) and who underwent complete resection with lymphadenectomy. We classified patients with small‐sized LCNEC (sLCNEC) into two subgroups based on immunostaining patterns with three neuroendocrine markers (chromogranin A, synaptophysin, and NCAM) and compared them to small‐sized SCLC (sSCLC). Results A total of 48 patients with sLCNEC and 39 patients with sSCLC were enrolled. Of 48 patients with sLCNEC, 21 were categorized as the small‐sized triple‐positive group (sTP), whose patients were positive for the three neuroendocrine markers, and 27 patients were categorized as the small‐sized nontriple‐positive group (sNTP), whose patients were not positive for all three neuroendocrine markers. The percentage of lymph node metastasis was significantly lower in sNTP than in sTP and sSCLC. There was no significant difference in overall survival, but recurrence‐free survival (RFS) and tumor‐specific survival (TSS) were significantly poorer in sTP and sSCLC than in sNTP. Multivariate analysis revealed sTP and sSCLC were independent prognostic factors for poorer RFS and TSS than those of sNTP. Conclusions The sNTP subgroup had a good prognosis and the sTP subgroup a poor prognosis. There were some similarities in clinicopathological features between sTP and sSCLC.https://doi.org/10.1111/1759-7714.13202Immunostaininglarge cell neuroendocrine carcinomaneuroendocrine markerssmall cell lung carcinomasmall‐sized tumors
collection DOAJ
language English
format Article
sources DOAJ
author Kazuhiro Minami
Yugo Tanaka
Hiroyuki Ogawa
Naoe Jimbo
Wataru Nishio
Masahiro Yoshimura
Tomoo Itoh
Yoshimasa Maniwa
spellingShingle Kazuhiro Minami
Yugo Tanaka
Hiroyuki Ogawa
Naoe Jimbo
Wataru Nishio
Masahiro Yoshimura
Tomoo Itoh
Yoshimasa Maniwa
Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma
Thoracic Cancer
Immunostaining
large cell neuroendocrine carcinoma
neuroendocrine markers
small cell lung carcinoma
small‐sized tumors
author_facet Kazuhiro Minami
Yugo Tanaka
Hiroyuki Ogawa
Naoe Jimbo
Wataru Nishio
Masahiro Yoshimura
Tomoo Itoh
Yoshimasa Maniwa
author_sort Kazuhiro Minami
title Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma
title_short Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma
title_full Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma
title_fullStr Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma
title_full_unstemmed Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma
title_sort neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma
publisher Wiley
series Thoracic Cancer
issn 1759-7706
1759-7714
publishDate 2019-11-01
description Abstract Background The aim of this study was to identify subgroups with good or bad prognosis in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) based on immunostaining patterns with neuroendocrine markers and compare them with small cell lung carcinoma (SCLC). Methods From January 2001 to December 2017, of all patients with resected LCNEC and SCLC, we selected patients whose pathological tumor sizes were ≤30 mm in diameter (defined as small‐sized tumors) and who underwent complete resection with lymphadenectomy. We classified patients with small‐sized LCNEC (sLCNEC) into two subgroups based on immunostaining patterns with three neuroendocrine markers (chromogranin A, synaptophysin, and NCAM) and compared them to small‐sized SCLC (sSCLC). Results A total of 48 patients with sLCNEC and 39 patients with sSCLC were enrolled. Of 48 patients with sLCNEC, 21 were categorized as the small‐sized triple‐positive group (sTP), whose patients were positive for the three neuroendocrine markers, and 27 patients were categorized as the small‐sized nontriple‐positive group (sNTP), whose patients were not positive for all three neuroendocrine markers. The percentage of lymph node metastasis was significantly lower in sNTP than in sTP and sSCLC. There was no significant difference in overall survival, but recurrence‐free survival (RFS) and tumor‐specific survival (TSS) were significantly poorer in sTP and sSCLC than in sNTP. Multivariate analysis revealed sTP and sSCLC were independent prognostic factors for poorer RFS and TSS than those of sNTP. Conclusions The sNTP subgroup had a good prognosis and the sTP subgroup a poor prognosis. There were some similarities in clinicopathological features between sTP and sSCLC.
topic Immunostaining
large cell neuroendocrine carcinoma
neuroendocrine markers
small cell lung carcinoma
small‐sized tumors
url https://doi.org/10.1111/1759-7714.13202
work_keys_str_mv AT kazuhirominami neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma
AT yugotanaka neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma
AT hiroyukiogawa neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma
AT naoejimbo neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma
AT watarunishio neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma
AT masahiroyoshimura neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma
AT tomooitoh neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma
AT yoshimasamaniwa neuroendocrinemarkerstainingpatterncategorizationofsmallsizedpulmonarylargecellneuroendocrinecarcinoma
_version_ 1724873191722057728